A new trading day began on Friday, with UroGen Pharma Ltd (NASDAQ: URGN) stock price down -0.91% from the previous day of trading, before settling in for the closing price of $15.41. URGN’s price has ranged from $3.42 to $17.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 10.39% over the past five years. Meanwhile, its annual earnings per share averaged 1.54%. With a float of $39.70 million, this company’s outstanding shares have now reached $46.10 million.
Let’s look at the performance matrix of the company that is accounted for 235 employees. In terms of profitability, gross margin is 89.68%, operating margin of -117.51%, and the pretax margin is -147.23%.
UroGen Pharma Ltd (URGN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of UroGen Pharma Ltd is 14.08%, while institutional ownership is 96.63%. The most recent insider transaction that took place on Jun 09 ’25, was worth 38,044. In this transaction Chief Medical Officer of this company sold 5,162 shares at a rate of $7.37, taking the stock ownership to the 153,378 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Officer proposed sale 5,162 for $7.37, making the entire transaction worth $38,044.
UroGen Pharma Ltd (URGN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 1.54% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Here are UroGen Pharma Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.18, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -1.09 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd (NASDAQ: URGN) saw its 5-day average volume 1.15 million, a negative change from its year-to-date volume of 1.61 million. As of the previous 9 days, the stock’s Stochastic %D was 78.94%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 95.72%, which indicates a significant increase from 82.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.81 in the past 14 days, which was lower than the 0.89 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.35, while its 200-day Moving Average is $10.98. Nevertheless, the first resistance level for the watch stands at $15.75 in the near term. At $16.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.66. If the price goes on to break the first support level at $14.84, it is likely to go to the next support level at $14.41. Assuming the price breaks the second support level, the third support level stands at $13.93.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
With a market capitalization of 705.49 million, the company has a total of 46,201K Shares Outstanding. Currently, annual sales are 90,400 K while annual income is -126,870 K. The company’s previous quarter sales were 20,250 K while its latest quarter income was -43,840 K.
